pharma news today obesity drugs glp-1 A $60 billion industry just found its next growth lever. π With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes glp-1 obesity drug supply news
Description
I wrote this article myself, and it expresses my own opinions
68 RoumesH.DumontU.SanchezS.MazuelL.BlancJ.RaffardG.et al (2021)
Synonyms Dasystephana scabra (Bunge), Japanese gentian, Gentiana fortune Hook
J., Dmarco, L., Castelao, A
- Oral semaglutide is effective, safe and well tolerated in patients with DM2, even in those with DKD, with the benefits inherent to this family of drugs, which may facilitate the earlier introduction of an arGLP-1 in the management of DM2
Foundayo was FDA-approved in April 2026 and is available at Endocare in Dubai and Abu Dhabi
